U.S. Markets closed
  • S&P Futures

    3,657.75
    +34.50 (+0.95%)
     
  • Dow Futures

    29,896.00
    +267.00 (+0.90%)
     
  • Nasdaq Futures

    12,389.50
    +112.50 (+0.92%)
     
  • Russell 2000 Futures

    1,843.80
    +23.70 (+1.30%)
     
  • Crude Oil

    44.98
    -0.36 (-0.79%)
     
  • Gold

    1,788.00
    +7.10 (+0.40%)
     
  • Silver

    22.96
    +0.37 (+1.62%)
     
  • EUR/USD

    1.1962
    +0.0027 (+0.2273%)
     
  • 10-Yr Bond

    0.8440
    +0.0020 (+0.24%)
     
  • Vix

    20.57
    -0.27 (-1.30%)
     
  • GBP/USD

    1.3358
    +0.0027 (+0.2017%)
     
  • USD/JPY

    104.4460
    +0.1220 (+0.1169%)
     
  • BTC-USD

    19,541.21
    +31.33 (+0.16%)
     
  • CMC Crypto 200

    383.43
    +18.84 (+5.17%)
     
  • FTSE 100

    6,266.19
    -101.39 (-1.59%)
     
  • Nikkei 225

    26,824.46
    +390.84 (+1.48%)
     

BMRN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of November 24, 2020 in the Class Action Filed on Behalf of BioMarin Pharmaceutical Inc. Limited Shareholders

Newsfile Corp.
·2 min read

New York, New York--(Newsfile Corp. - October 21, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) alleging that the Company violated federal securities laws.

Class Period: February 28, 2020 and August 18, 2020
Lead Plaintiff Deadline: November 24, 2020

Learn more about your recoverable losses in BMRN:
http://www.kleinstocklaw.com/pslra-1/biomarin-pharmaceutical-inc-loss-submission-form?id=10368&from=5

The filed complaint alleges that BioMarin Pharmaceutical Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) differences between the Phase 1/2 and Phase 3 study of valoctocogene roxaparvovec, an investigational adenoassociated virus gene therapy, limited the reliability of the Phase 1/2 study to support valoctocogene roxaparvovec's durability of effect; (ii) as a result, it was foreseeable that the U.S. Food and Drug Administration would not approve the Biologics License Application for valoctocogene roxaparvovec without additional data; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Shareholders have until November 24, 2020 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

For additional information about the BMRN lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click the link above.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/66592